Earlier this week, Dr. James Allison and Dr. Tasuku Honjo were announced as joint winners of the 2018 Nobel Prize in Physiology or Medicine for their work in the field of immunotherapy and checkpoint immune regulation. Their studies have sparked decades of clinical advances, and changed the future of cancer therapy. A webinar presented by Dr. Allison in conjunction with Dr. Gordon Freeman and Dr. Philip Gotwals is featured in this week's blog post.
Research trends in macrophage plasticity
It’s an exciting time for immuno-oncology research, as potential predictive biomarkers from an expanding collection of cell types are being pursued. Explore the plasticity of tumor-associated macrophages (TAMs) and challenges in distinguishing M1- versus M2- functional states in this 5-minute video featuring CST Developmental Scientist Sarah Klein, PhD.
Can't see the embedded video? Click here to watch.
Multiple myeloma (MM) is a type of hematopoietic malignancy characterized, in part, by bone pain, anemia, kidney failure, and recurring infections. The underlying mechanism that drives the disease is abnormal proliferation and accumulation of malignant plasma cells in the bone marrow that secrete large amounts of abnormal antibodies.
In Mr. D’s sophomore English class, almost no subject was taboo or off limits. Even with our class projects, he encouraged us to pursue topics that truly interested us, and sometimes that meant having to educate Mr. D about something entirely new to him. But if your presentation included stunning visuals, you had to be prepared to paint a word picture. Macular degeneration rendered his otherwise healthy eyes all-but-useless.
The last few years have witnessed several breakthroughs in the immuno-oncology space. Treatments that harness the body’s immune system to fight cancer have transitioned from speculation to offering endless possibilities for drug discovery. Of these treatments, therapeutic monoclonal antibodies are positioned at the forefront of the immunotherapy revolution, and the FDA has approved several of these monoclonal antibodies to treat cancer.